Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | DRD5 | P21918 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736736 | 0.93 | HDAC1 (0.48) | KDM4EMAPTTDP1HDAC1HDAC6 | |
| SCHEMBL1735358 | 0.90 | MTNR1A (0.43) | KDM4EMAPTTDP1HDAC1HDAC6 | |
| SCHEMBL1735276 | 0.84 | ALOX15 (0.45) | KDM4EMAPTTDP1HDAC1HDAC6 | |
| SCHEMBL1736709 | 0.83 | HDAC1 (0.48) | KDM4EMAPTTDP1HDAC1HDAC6 | |
| SCHEMBL1736753 | 0.82 | HRH3 (0.47) | KDM4EMAPTTDP1HDAC1HDAC6 | |
| SCHEMBL1734458 | 0.81 | HTR2A (0.48) | HDAC1HDAC6ALOX15DRD2HTR2C | |
| SCHEMBL1735399 | 0.81 | ALOX15 (0.45) | HDAC1HDAC6ALOX15HTR2BFNTA | |
| SCHEMBL1735449 | 0.81 | RORC (0.41) | KDM4EMAPTTDP1HDAC1HDAC6 | |
| SCHEMBL1735405 | 0.78 | TAAR1 (0.39) | KDM4EMAPTTDP1HDAC1HDAC6 | |
| SCHEMBL1736518 | 0.78 | ALDH1A1 (0.42) | ALOX15ALDH1A1BIRC2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086959-B1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20110264029-A1 | IONTOPHORETIC DELIVERY SYSTEM | Kopman, Stanley E. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2086959-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | TAAR1, TAAR5, MCHR1 | KDM4E 4550/4885MAPT 408/4885TDP1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.